Changes in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a 1-year period at a specialized clinic in Mexico

References

• Info, AIDS, and US Department of Health and Human ServicesGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsUSAOffice of AIDS Research Advisory Council (OARAC)20131267 Available from: https://aidsinfo.nih.gov/content-files/adultandadolescentgl003371.pdfAccessed September 14, 2018
   Google Scholar
• RodgerAJLodwickRSchechterMMortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general populationAIDS201327697397923698063
   PubMed Web of Science ®Google Scholar
• CurrierJSLundgrenJDGuidelines for managing cardiovascular risk: an evolving areaCurr Opin HIV AIDS20083320520619372967
   PubMed Web of Science ®Google Scholar
• AboudMElgalibAPomeroyLCardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 studyInt J Clin Pract20106491252125920653801
   PubMed Web of Science ®Google Scholar
• FabbianiMCiccarelliNTanaMCardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patientsHIV Med201314313614422994586
   PubMed Web of Science ®Google Scholar
• Friis-MøllerNWeberRReissPCardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS20031781179119312819520
   PubMed Web of Science ®Google Scholar
• Li VecchiVMaggiPRizzoMMontaltoGThe metabolic syndrome and HIV infectionCurr Pharm Des201420314975500324320034
   PubMed Web of Science ®Google Scholar
• GrinspoonSCarrACardiovascular risk and body-fat abnormalities in HIV-infected adultsN Engl J Med20053521486215635112
   PubMed Web of Science ®Google Scholar
• DesvarieuxMBoccaraFMeynardJLInfection duration and inflammatory imbalance are associated with atherosclerotic risk in HIV-infected never-smokers independent of antiretroviral therapyAIDS201327162603261424100713
   PubMed Web of Science ®Google Scholar
• GrinspoonSKGrunfeldCKotlerDPState of the Science ConferenceCirculation200811819821018566320
   PubMed Web of Science ®Google Scholar
• FeinsteinMJNanceRMDrozdDRAssessing and Refining Myocardial Infarction Risk Estimation Among Patients With Human Immunodeficiency Virus: A Study by the Centers for AIDS Research Network of Integrated Clinical SystemsJAMA Cardiol20162155162
   Web of Science ®Google Scholar
• SecretaríaSGuía de manejo antirretroviral de las personas que viven con VIHMéxicoSecretarıa de Salud, Gobierno de México2014 Available from: http://www.censida.salud.gob.mx/descargas/principal/Guia_ARV_2014V8.pdfAccessed September 14, 2018
   Google Scholar
• DubéMPSteinJHAbergJAGuidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials GroupClin Infect Dis200337561362712942391
   PubMed Web of Science ®Google Scholar
• LichtensteinKAArmonCBuchaczKProvider compliance with guidelines for management of cardiovascular risk in HIV-infected patientsPrev Chronic Dis201310E1023347705
   PubMed Web of Science ®Google Scholar
• ChamnanPSimmonsRKSharpSJRepeat Cardiovascular Risk Assessment after Four Years: Is There Improvement in Risk Prediction?PLoS One2016112e014741726895071
   PubMed Web of Science ®Google Scholar
• SteinJHManaging cardiovascular risk in patients with HIV infectionJ Acquir Immune Defic Syndr200538211512315671795
   PubMed Web of Science ®Google Scholar
• WilliamsLNational Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation200210625314342112485966
   PubMed Web of Science ®Google Scholar
• GuevaraFOCañónBLiévanoMCPrevalencia de síndrome metabólico en pacientes infectados con VIH [Prevalence of metabolic syndrome in HIV infected patients]Acta Med Colomb200833283
   Google Scholar
• SamarasKWandHLawMPrevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteriaDiabetes Care20073011311917192343
   PubMed Web of Science ®Google Scholar
• KrishnanSSchoutenJTAtkinsonBMetabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individualsJ Acquir Immune Defic Syndr201261338138922828718
   PubMed Web of Science ®Google Scholar
• Data Collection on Adverse Events of Anti-HIV Drugs Study GroupSabinCAd’Arminio MonforteAChanges over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarctionClin Infect Dis20084671101111018461712
   PubMed Web of Science ®Google Scholar
• GrinspoonSKMetabolic syndrome and cardiovascular disease in patients with human immunodeficiency virusAm J Med2005118232815639205
   PubMed Web of Science ®Google Scholar
• Mary-KrauseMCotteLSimonAClinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected menAIDS2003172479248614600519
   PubMed Web of Science ®Google Scholar
• CraneHMvan RompaeySEKitahataMMAntiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapyAIDS20062071019102616603854
   PubMed Web of Science ®Google Scholar
• RiddlerSASmitEColeSRImpact of HIV infection and HAART on serum lipids in menJAMA2003289222978298212799406
   PubMed Web of Science ®Google Scholar
• BozzetteSAAkeCFTamHKChangSWLouisTACardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infectionN Engl J Med2003348870271012594314
   PubMed Web of Science ®Google Scholar
• CarrASamarasKThorisdottirADiagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort studyLancet199935391702093209910382692
   PubMed Web of Science ®Google Scholar
• BehrensGDejamASchmidtHImpaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitorsAIDS19991310F63F7010416516
   PubMed Web of Science ®Google Scholar
• Friis-MøllerNWeberRReissPCardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD studyAIDS20031781179119312819520
   PubMed Web of Science ®Google Scholar
• CibriánASánchezMAGarcíaSChanges in cardiovascular risk and clinical outcomes in a HIV/AIDS cohort study over a one-year period at a specialized clinic in Mexico2017
   Google Scholar